AlphaMED Resources · https://alphamedicine.uk/Resources/cases/neuralink-uk
Neuralink UK brain implant trial
A brain implant made by* Neuralink *was first placed in a UK patient at University College London Hospitals in October 2025. It is a research trial, not a treatment, and its results have not yet been published in a peer reviewed journal.
- Study start date recorded on ClinicalTrials.gov
- First UK Neuralink implant at UCLH
- UCLH reports seven participants, all operated on between October and December 2025
- A participant's story is reported, and the findings are not yet peer reviewed
Summary
- The Neuralink N1 implant sits in the skull, with electrode threads that a robot inserts into the brain. It records brain signals so a paralysed person can control a computer by thought.
- People with severe paralysis have few options. The chief investigator says the implant has "the potential to help thousands of patients trapped in their own bodies", but the device is unproven.
- The implant is an investigational device approved for this study by four bodies, including the Medicines and Healthcare products Regulatory Agency and the Health Research Authority.
- The first UK patient, who had motor neurone disease, moved a cursor the next day and went home.
- UCLH reported on 29 January 2026 that seven participants had been operated on by December 2025, the full number planned.
- The registry still lists the trial as recruiting, with seven as the estimated enrolment, and was last updated in August 2025.
Dig deeper
- The registry requires participants to be at least 18 with a stable caregiver, and a spinal cord injury, brainstem stroke or ALS (motor neurone disease) that significantly impairs hand control of a computer, phone or tablet.
- The primary outcomes are device and procedure related adverse events, so the headline measure is harm. Synchron's trial reported no serious implant related adverse events in six participants at 12 months, presented at a 2024 conference.
- Fellows at a bioethics think tank have warned that "science by press release, while increasingly common, is not science". The same question of early results arose in the AI designed coronavirus vaccine trial.
- Neither the UCLH release nor the Euronews report says what happens to the implant after the study. IEEE Spectrum reported in 2022 that users of the Second Sight Argus II retinal implant were left with obsolete, unsupported devices.
- Scientists and ethicists worry about hacking, blackmail and privacy, because the devices access users' thoughts.
Ethical issues
| Principle | How it applies here |
|---|---|
| Autonomy | The Mental Capacity Act presumes adults have capacity, and its test asks whether an impairment of the mind or brain stops a decision, so paralysis alone does not remove the right to choose. Research on someone who lacks capacity is unlawful unless approved under section 31, and the sources read do not say how this trial meets that test. |
| Beneficence | The study evaluates whether the implant is safe and functional, not whether it helps. The first patient hoped for more freedom, but no benefit has been published. |
| Non maleficence | The robot places the threads, and device and procedure harm is the main outcome. The conflict is between a patient's hope for benefit and the duty to avoid harm while the device is unproven. |
| Justice | The trial has seven places, all used at UCLH so far, with Neuralink Corp as lead sponsor. The sources read do not say who keeps the implant or pays for support after the study. |
Interview questions
- What do you know about the Neuralink trial at University College London Hospitals?
- What has the first UK patient shown, and what has not yet been shown?
- What is the difference between a research device and a treatment, and why does it matter to a patient?
- Who decides whether an adult can agree to join a trial like this, and what test do they apply?
- You are the junior doctor on a neurology ward, and a patient with motor neurone disease asks whether to join. What do you tell them?
- What happens to a patient who relies on a device when the study ends?
- What is the case for and against a company, rather than the NHS, controlling a device in a trial?
Sources
- uclh.nhs.ukuclh.nhs.uk/…/first-uk-patient-uses-thought-control-computer-hours-after-n
- uclh.nhs.ukuclh.nhs.uk/…/seven-gb-prime-patients-now-participating-neuralink-trial
- clinicaltrials.govclinicaltrials.gov/…/NCT07127172
- healio.comhealio.com/…/no-serious-adverse-events-reported-with-synchron-braincomput
- theconversation.comtheconversation.com/…/several-companies-are-testing-brain-implants-why-is-there-so
- euronews.comeuronews.com/…/paralysed-british-student-controls-computer-with-thoughts-us
- spectrum.ieee.orgspectrum.ieee.org/…/bionic-eye-obsolete
- legislation.gov.uklegislation.gov.uk/…/1
- legislation.gov.uklegislation.gov.uk/…/2
- legislation.gov.uklegislation.gov.uk/…/31
Photo: Jesse Emspak, Public domain, via Wikimedia Commons, colour altered.
How to answer these is in the course
The Interview Masterclass teaches you how to answer, then puts you in front of mock panels marked by more than one mentor. Our offer rate is 93% across all cycles since 2022.
alphamedicine.uk/Services · alphamedicine.uk/Results
More NHS hot topics, medical ethics case studies and medical school interview questions are in AlphaMED Resources, which we add to and update through the application cycle.